Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -6.67%41 Market Cap is $160.26 Mil as of Jul. 21, 2026. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,022 Drug Manufacturers companies, ADC Therapeutics ranks worse than 54.21% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ADC Therapeutics's share price for the quarter that ended in Mar. 2026 was $3.75. ADC Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 127.17 Mil. Therefore, ADC Therapeutics's market cap for the quarter that ended in Mar. 2026 was $476.87 Mil.
ADC Therapeutics's quarterly market cap
declined
from Sep. 2025 ($450.51 Mil) to Dec. 2025 ($443.89 Mil) but then
increased
from Dec. 2025 ($443.89 Mil) to Mar. 2026 ($476.87 Mil).
ADC Therapeutics's annual market cap
increased
from Dec. 2023 ($136.61 Mil) to Dec. 2024 ($196.73 Mil) and
increased
from Dec. 2024 ($196.73 Mil) to Dec. 2025 ($443.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ADC Therapeutics's Enterprise Value for Today is $45.92 Mil.
ADC Therapeutics (NYSE:ADCT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ADC Therapeutics Market Cap Related Terms
ADC Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ADC Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADC Therapeutics (ADCT) has a Market Cap of $160.26 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ADC Therapeutics and its competitors. According to the industry distribution chart, ADC Therapeutics ranks #554 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is ADC Therapeutics' Market Cap too high?
ADC Therapeutics' current Market Cap is $160.26 Mil. The Drug Manufacturers industry median Market Cap is 222.28. ADC Therapeutics' value of $160.26 Mil is 27.9% below this industry median. Based on the distribution chart, ADC Therapeutics ranks #554 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Market Cap compare to GNLX and VXRT?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #554 out of 1022 companies for Market Cap. This places ADC Therapeutics in the lower half of its industry. The industry median Market Cap is 222.28. ADC Therapeutics' value of $160.26 Mil is 27.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 222.28, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current Market Cap of $160.26 Mil is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 222.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Market Cap is $160.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current Market Cap is $160.26 Mil and 27.9% below the Drug Manufacturers industry median of 222.28. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Market Cap is $160.26 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Market Cap: $160.26 Mil
GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
Industry Position: 27.9% below the Drug Manufacturers median (#554 of 1022)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
